Close
Smartlab Europe
Inizio Ignite

Sever Pharma Solutions breaks ground with new high potency drug manufacturing suites

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Injectable Drug Formulation Trends in Biopharma

Analysis of the evolving landscape of parenteral delivery, focusing on the stability of high-concentration biologics and the integration of patient-centric delivery devices.

ACG Packaging Materials Joins WEF Global Lighthouse Network

ACG Packaging Materials has announced that its Shirwal manufacturing...

Future Trends in Pharmaceutical Drug Delivery Platforms

Forward-looking perspective on the convergence of digital technology, bioengineering, and material science in creating the next generation of therapeutic delivery systems.
- Advertisement -

Sever Pharma Solutions, a leading pharmaceutical contract development and manufacturing organization (CDMO), has announced the groundbreaking of its new high potency active pharmaceutical ingredients (HPAPI) manufacturing suites. The company’s investment in these new state-of-the-art manufacturing facilities will allow them to better serve pharmaceutical clients seeking the rare combination of HPAPI Drug Product development, clinical and commercial manufacturing, and Hot Melt Extrusion processing.

Sever Pharma Solutions has an extensive history of developing and manufacturing HPAPI drug products like contraceptive vaginal rings at their site in Malmö, Sweden. The new suites in Putnam will feature the latest extrusion technologies, facilities, and containment equipment to provide clients with the ability to develop and manufacture polymer-based HPAPI drug products such as long-acting implants and inserts and amorphous solid dispersions while meeting rigorous quality standards. Sever Pharma Solutions’ new HPAPI suites will also offer increased capacity and flexibility, ready to supply end-to-end solutions to meet the ever-increasing demands of the pharmaceutical industry.

“We are excited to announce the groundbreaking of our new high potency drug manufacturing suites,” said Kenneth Stokholm, CEO of Sever Pharma Solutions. “With this significant investment, we have responded to our client and industry needs to provide this combination of polymer-based formulations for high potent drugs. We will continue to provide our clients with world-class manufacturing capabilities that help them improve the lives of patients worldwide.”

Sever Pharma Solutions acquired the Putnam, CT, facility in late 2021 with an eye toward this expansion. The Putnam facility has been developing extrusion-based formulations for clients since 2005 and moved into the current GMP manufacturing facility in 2015. The additional new manufacturing suites are expected to be fully operational by November 2023, enabling Sever Pharma Solutions to continue delivering innovative pharmaceutical solutions for its clients.

Latest stories

Related stories

Injectable Drug Formulation Trends in Biopharma

Analysis of the evolving landscape of parenteral delivery, focusing on the stability of high-concentration biologics and the integration of patient-centric delivery devices.

ACG Packaging Materials Joins WEF Global Lighthouse Network

ACG Packaging Materials has announced that its Shirwal manufacturing...

Future Trends in Pharmaceutical Drug Delivery Platforms

Forward-looking perspective on the convergence of digital technology, bioengineering, and material science in creating the next generation of therapeutic delivery systems.

Advancing Drug Formulation Stability in Modern Pharma

Exploration of the chemical, physical, and environmental factors that compromise the integrity of modern therapeutics, and the advanced testing protocols used to ensure safety.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »